After all, if a company has excellent prospects, investors will flock to its shares, bidding them up. For two examples, consider Editas Medicine (NASDAQ: EDIT) and Snap (NYSE: SNAP). Editas Medicine is a biotech company that focuses on gene-editing therapies. Read More...
TipRanks
Down More Than 50%: These 2 ‘Strong Buy’ Stocks Are Flirting With a Bottom
There are conflicting signals coming from the markets lately. We all know the accumulated headwinds; rising interest rates, the banking failures, and the Fed, in the minutes from its last FOMC meeting, indicated that a ‘mild’ recession is highly likely in the second half of this year. Yet, the markets have seen sound gains year-to-date, with the S&P 500 up 7.5% and the NASDAQ an even better 15%. Looking at the current market conditions, Jeremy Siegel, a Wharton economic professor and a long-time
Add Comment